Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Puff Puff Post

JANUARY 1, 2020

One particularly promising area of research is in the treatment of cancer. Cancer patients suffer not only from cancer, but the damaging effects of treatment. Cannabis Cancer Treatments as an Alternative to Opioids. Therefore doctors now consider cannabis as the better treatment option. In some cases opiods work better.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. tetrahydrocannabinol (THC).

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

MGC Pharma

FEBRUARY 20, 2018

Cannabis is an effective tool for the treatment of topical skin conditions In a recent study by undertaken by MGC Pharma, our dermatologists found that CBD is effective in providing relief for relief for dry, red, flakey, oily and acne prone skin through CBD skincare. Notably, 41% of the Cannabis users stopped using opioids altogether.

Research and Development 100

Research and Development Clinical Trials Patients Chronic Pain 100

Cannabis Law Report

AUGUST 21, 2019

Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. If you wish to re-publish this story please do so with following accreditation. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

MedicalJane

JUNE 29, 2018

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome. Prior to this week, the U.S. “It’s fantastic.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. tetrahydrocannabinol (THC).

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

DECEMBER 18, 2019

Notably, the increase comes after the company recently broke into the European pharma-market after getting green-lighted from the Irish Government to sell its phytocannabinoid-derived “CannEpil” product to epilepsy sufferers. We continue on an upward trajectory, as we’ve increased our prescription numbers by more than 25% is just a few weeks.

Research and Development 59

Research and Development Clinical Trials Seed-To-Sale Pharmaceutical 59

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 1, 2021

Because it can cross the blood-brain barrier and gain access to the central nervous system (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related disorders. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. The company initiated the first legal transfer (as deemed by federal law) to the U.S.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. On Tuesday, January 24, several legislative bills were unveiled by the Japanese government.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

MMJ Recs

DECEMBER 22, 2023

The AIDS epidemic in the 1980s brought attention to the potential benefits of marijuana in alleviating symptoms such as nausea and appetite loss associated with the disease and its treatment. Studies have shown the efficacy of medical cannabis in treating conditions such as chronic pain, epilepsy, and certain mental health disorders.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Info

OCTOBER 11, 2019

Epidiolex is an epilepsy-fighting cannabis base drug produced by GW Prescription drugs. The strawberry-flavored oral CBD treatment stops seizures, and accommodates clobazam. In Europe, there are round 50,000 young adults and children affected by one of many two signs of epilepsy.

Business 45

Business Epilepsy Clinical Trials Treatment 45

Canna Care Docs

DECEMBER 16, 2020

It would feel like an out-of-body experience, except for one fact: your body is constantly reminding you of those symptoms you’ve been suffering from all this time, putting treatment on the back burner while you deal with life as we know it. In several clinical studies, marijuana use seemed to improve mood for those with reactive depression.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

The Cannigma

JUNE 15, 2021

The first clinical research done on CBD as a potential treatment for epilepsy was in 1980, but the information gleaned didn’t make its way to the public eye until decades later. CBG, however, also has some medicinal potential that CBD doesn’t, for instance as a treatment for hypertension and insulin resistance.

CBD 122

CBD Research and Development Epilepsy Extraction 122

CannaTech

SEPTEMBER 16, 2018

Doctors have remained integral parts of a patient’s cannabis journey through what is known as the Access to Cannabis for Medical Purposes Regulation (ACMPR) act. Shedding Stigma and Promoting Patient Access. Patient access also hinges on a doctor’s preconceived notions of cannabis.

Education 66

Education Medicine Clinical Trials Patients 66

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. “For The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 23, 2021

It’s also important to note that MYMD-1 shows promise in pre-clinical studies as a treatment for immune diseases including rheumatoid arthritis, multiple sclerosis, and Hashimoto’s thyroiditis, and as an anti-fibrotic and anti-proliferation therapeutic.”.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

“This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JANUARY 13, 2020

commercial and government payors to ensure that appropriate patients have access to Epidiolex with as few restrictions as possible. Nabiximols (known as “Sativex” outside US) in the US: Commence pivotal clinical program in initial target indication of spasticity associated with Multiple Sclerosis. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The popularity of medical cannabinoids (MCs) treatment is growing, as more countries enable MCs treatment for various indications in adults 1. Metrics details. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

APRIL 10, 2019

MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.

Clinical Trials 51

Clinical Trials Epilepsy Medicine Research and Development 51

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Steve Barbera is an accomplished cross-functional leader in the healthcare industry, with over 20 years of experience in the development and implementation of complex market access strategies including health policy, pricing and reimbursement, contracts and coding.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Veriheal

AUGUST 31, 2020

Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

The Cannigma

MAY 7, 2021

The Cannabis Enigma podcast is a co-production of The Cannigma and Americans for Safe Access. You’ve had this conversation in the US for over 20 years in some states so it’s not as if suddenly overnight, people have woken up to the discussion of cannabis and cannabis legalization and cannabis access. Music by Desca.

Supply Chain 120

Supply Chain Patients Access Hemp 120

Cannabis Law Report

JULY 15, 2019

Law 33/2018 set the framework for the regulation of the use of cannabis-based medicinal products, preparations and substances that would effectively allow Portuguese patients to access medical cannabis What really has changed during the last year? The hardest part has already been done.

Medicine 40

Medicine Clinical Trials Patients Access 40

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. It was also used as a topical treatment for haemorrhoids, ear infection, and wounds (Aldrich 1997 ; Touw 1981 ).

Research and Development 52

Research and Development Medicine Access Media 52

Greencamp

AUGUST 16, 2018

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Exploring the available research on ALS and cannabinoids.

Strains 94

Strains Cannabinoids Research and Development Indica 94

The Cannigma

DECEMBER 22, 2021

The Cannabis Enigma is a co-production of The Cannigma and Americans for Safe Access. We’ve got our regular segment with Americans for Safe Access. We have autism and epilepsy. We do participate in clinical trials that are initiated by others, and we will have our own clinical trial using terpene formulations in oil.

Research and Development 79

Research and Development Oil Cannabis Clinical Trials 79

Cannabis Law Report

JANUARY 20, 2022

Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines. Eleusis designed ELE-Psilo, a proprietary psilocybin-based drug candidate that is formulated for IV infusion and in development for the treatment of depression.

Therapy 52

Therapy Research and Development Business Access 52

Cannabis Law Report

JULY 15, 2022

They then go off to their separate sections, which are again all controlled by biometric fingerprint scanning for access,” Mr Benjamin said. Workers will have their fingerprints scanned before being allowed to access the turnstile to the Medifarm facility. ( “They get changed. ABC Rural: Jennifer Nichols ).

Medicine 52

Medicine Patients Media Supply Chain 52